

BeiGene Proudly Sponsors

**Chinese American Hematologists  
and Oncologists Network (CAHON)**

**New York Oncology Forum**

**2020 Virtual Series**

**CANCER HAS  
NO BORDERS.  
NEITHER  
DO WE<sup>®</sup>**

**Website:** [www.beigene.com](http://www.beigene.com)

**Twitter:** @BeiGeneUSA

**LinkedIn:** [www.linkedin.com/company/BeiGene](http://www.linkedin.com/company/BeiGene)

**BeiGene**

# The BeiGene Story

## A global biotechnology innovator focused on improving treatment outcomes and patient access

BeiGene is a fully-integrated biotechnology company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, one of the youngest ever U.S. Academy of Science members and Director of China's National Institute of Biological Sciences (NIBS) in Beijing. The two set out to build a unique company that was globally focused from its inception.


BeiGene (NASDAQ: BGNE; HKEX 06160) focuses on developing novel therapies where there is global unmet need.

**4,200+**  
employees

(as of August 6, 2020)

**10** offices  
on 4 continents

Trials in **35**  
countries and regions



Our broad product portfolio and pipeline include:

- 3 wholly owned late-stage oncology candidates, including one approval in the U.S. and four approvals in China
- 27 Phase 3 or potentially registration-enabling trials ongoing, 60+ studies in total
- 32 clinical or commercial stage assets including seven internally developed and 25 in-licensed

BeiGene has built a strong innovative pipeline of clinical drug candidates through internal discovery and collaborations.

**BeiGene**

# Tislelizumab Broad Late-stage Development Program

## Sixteen filed or potentially registration-enabling studies

Lung	Phase 3 (n=320) in 1L Stage IIIB or IV <u>non-squamous</u> NSCLC tislelizumab+ chemo (platinum-pemetrexed) vs. chemo, PE: PFS Initiated: Jul 2018, Enrollment complete <sup>^</sup> : Aug 2019, sNDA accepted Jun 2020	Phase 3 (n=360) in 1L Stage IIIB or IV <u>squamous</u> NSCLC tislelizumab+ paclitaxel and carboplatin combo or nab-paclitaxel and carboplatin combo vs. paclitaxel and carboplatin combo, PE: PFS Enrollment complete <sup>^</sup> : Aug 2019, sNDA accepted Apr 2020
	Phase 3 (n=800) in 2L NSCLC tislelizumab vs. docetaxel, PE: OS Initiated: Nov 2017	Phase 3 (n=364) in 1L SCLC Tislelizumab+ chemo (Carboplatin/Cisplatin, Etoposide) vs. placebo + chemo, PE: PFS, OS Initiated: July 2019
	Phase 3 (n=380) Neoadjuvant in Stg II/IIIA NSCLC Tislelizumab+ chemo (Platinum doublet) vs. placebo + chemo, followed by tislelizumab or placebo Initiated: May 2020	GC Phase 3 (n=720) in 1L advanced GC tislelizumab or placebo + platinum- and fluoropyrimidine-based chemo, Co-PE: PFS and OS Initiated: Dec 2018
HCC	Phase 3 (n=640) in 1L HCC tislelizumab vs. sorafenib, PE: OS Initiated: Jan 2018, Enrollment complete <sup>^</sup> : Nov 2019	Phase 2 (n=225) in 2L/3L HCC tislelizumab monotherapy, PE: ORR by IRC Initiated: Apr 2018, Enrollment complete <sup>^</sup> : Feb 2019, sNDA accepted Jul 2020
ESCC	Phase 3 (n=450) in 2L ESCC tislelizumab vs. single-agent chemo (paclitaxel, docetaxel, or irinotecan), PE: OS Initiated: Jan 2018, Enrollment complete <sup>^</sup> : 1Q20	Phase 3 (n=480) in 1L advanced ESCC tislelizumab or placebo + platinum- and fluoropyrimidine-based chemo, Co-PE: PFS and OS Initiated: Dec 2018
	Phase 3 (n=316) in localized ESCC tislelizumab + chemoradiotherapy vs chemoradiotherapy, PE: OS Initiated: May 2019	MSI-H or dMMR solid tumors Pivotal phase 2 (n=60) in MSI-H or dMMR solid tumors tislelizumab monotherapy, PE: ORR Initiated: Sep 2018
UC	Pivotal phase 2 (n=110) in 2L UC tislelizumab monotherapy, PE: ORR, Initiated: Jul 2017 Enrollment complete: Aug 2018, NDA accepted in May 2019 and approved by NMPA in May 2020	Phase 3 (n=420) in 1L UC tislelizumab + chemo (cisplatin + carboplatin + gemcitabine) vs placebo + chemo PE: OS Initiated: June 2019
CHL	Pivotal phase 2 (n=70) in R/R cHL tislelizumab monotherapy, PE: ORR Initiated: Apr 2017, Enrollment complete: Nov 2017, NDA accepted in Aug 2018 and approved by NMPA Dec. 2019	NPC Phase 3 (n=256) in 1L tislelizumab + chemo (gemcitabine plus cisplatin) vs. placebo + chemo PE: PFS Initiated: Apr 2019



<sup>^</sup>Time of the announcement of the enrollment completion; <sup>^</sup>Tislelizumab dosage 200mg every three weeks, Q3W. Global Ph2 in R/R/ NK/T-cell lymphoma and Ph2 trial in MSI-H or dMMR solid tumors in China are potentially registration-enabling trials. 1/2L: First/Second Line; cCRT: concurrent chemoradiotherapy; cHL: Classical Hodgkin's Lymphoma; ESCC: Esophageal Squamous-Cell Carcinoma; GC: Gastric Cancer; HCC: Hepatocellular Carcinoma; IRC: Independent Review Committee; ITT: Intent-to-treat; MSI-H or dMMR: Microsatellite Instability High or Deficient Mismatch Repair; NDA: New Drug Application; NK: Natural Killer; NSCLC: Non-Small Cell Lung Cancer; ORR: Overall response rate; OS: Overall survival; PE: Primary Endpoint; PFS: Progression-free survival; R/R: Relapsed / Refractory; UC: Urothelial Carcinoma;